The Fragility Index in a Cohort of HIV/AIDS Randomized Controlled Trials.

ABSTRACT: HIV/AIDS is associated with significant morbidity, mortality, and financial burden. For these reasons, robust clinical evidence is critical. We aim to investigate the fragility index, fragility quotient, and risk of bias of clinical trial endpoints in HIV medicine. The fragility index represents the minimum amount of trial endpoint "nonevents" changed to "events" in one trial arm required to nullify statistical significance. The fragility quotient contextualized the fragility index by dividing the index by the total trial sample size. We selected eligible trials from the Department of Health and Human Services guideline for the use of antiretroviral agents in HIV-1-infected adults and adolescents. We calculated the fragility index and fragility quotient for all included trials. The Cochran

SUBMITTER: Wayant C 

PROVIDER: S-EPMC6614212 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature